Devyser Diagnostics AB (Nasdaq: DVYSR) (STO:DVYSR), a provider of genetic test kits for laboratories, on Tuesday declared financial information for its full year from January to December 2022.

The company reported a loss after tax of SEK46.0m, compared to a loss of SEK20.7m in the previous year.

Earnings per share before and after dilution amounted to a loss of SEK2.89 in 2022, versus a loss of SEK1.85 in the year before.

Net sales increased by 35.4% to SEK126.6m, over SEK93.5 in 2021.

Devyser added that its board proposes no dividend for 2022.